For type 2 diabetes mellitus in multiple clinical settings. ANDA 202467, held by Macleods Pharms Ltd. Pioglitazone Hydrochloride.
As of Nov 16, 2026, ANDA 202467 (Pioglitazone Hydrochloride), held by Macleods Pharms Ltd, was first approved by FDA on Feb 6, 2013, with 4 approved supplements and 0 published complete response letters.
Monotherapy and Combination Therapy Pioglitazone tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings. Important Limitations of Use Pioglitazone tablets exerts its antihyperglycemic effect only in the presence of endogenous insulin. Pioglitazone tablets should not be used to treat type 1 diabetes or diabetic ketoacidosis, as it would not be effective in these settings. Use caution in patients with liver disease. Pioglitazone hydrochloride is a thiazolidinedione and an agonist for peroxisome proliferator-activated receptor (PPAR) gamma
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 6, 2013 | Original application | Approved |
| Pioglitazone HydrochlorideEQ 15MG BASE · tablet;oral | Pioglitazone Hydrochloride | Rx |
| Pioglitazone HydrochlorideEQ 30MG BASE · tablet;oral | Pioglitazone Hydrochloride | Rx |
| Pioglitazone HydrochlorideEQ 45MG BASE · tablet;oral | Pioglitazone Hydrochloride | Rx |
| Jun 7, 2023 | Supplement 23Labeling · Standard review | Approved | None posted |
| Dec 17, 2018 | Supplement 9Labeling · Standard review | Approved | None posted |
| Dec 17, 2018 | Supplement 12Labeling · Standard review | Approved | None posted |
| Jan 26, 2016 | Supplement 4Labeling · Standard review | Approved | None posted |
| Feb 6, 2013 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters